PCI Pharma Services (PCI) has announced the promotion of Mark Shepanski to Executive Director of Operations and Site Lead of its San Diego facilities. He will report to Brad Payne, PCI’s Senior Vice President of Global Operations.
In his new role at PCI, Shepanski will ensure that the San Diego Center of Excellence continues to deliver fast, flexible, and reliable clinical services.
The site features services focused on packaging, labelling, and logistical support activities for investigational drug products including advanced cold chain logistics for global clinical studies.
With more than 17 years of experience leading operational and quality teams, Shepanski had previously led operational and quality teams at Sherpa Clinical Packaging, which was acquired by PCI on October 1, 2018. He served as Senior Director of Quality at Sherpa.
“I foresee exciting capability expansion possibilities at our San Diego location as we continue to develop a comprehensive global suite of services to help our clients bring their molecule to market. I look forward to driving the operational processes here that will support the fast, flexible, and reliable clinical services that our clients expect," Shepanski commented.
Commenting on the appointment, Payne noted: “Mark brings valuable experience from his years at Sherpa, and his considerable experience in diverse sectors of the biopharmaceutical and medical device industries. His commitment to advancing our operational processes and expert team at the San Diego site will be instrumental to ensuring that our customers continue to receive best-in-class clinical services.”
PCI has been actively investing in its global clinical services portfolio, with the Sherpa acquisition being the third in the past 12 months.
In October 2017, PCI acquired contract packaging services provider Millmount Healthcare based in Dublin, Ireland. Later in March 2018, it acquired Pharmaceutical Packaging Professionals in Melbourne, Australia, bolstering its capability for early phase clinical study as well as adding new clinical scale drug manufacture capabilities, including sterile and non-sterile delivery forms.
